Exits

EpiTherapeutics

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested in 2010

Acquired by Gilead in 2015

Based in Foster City, California, USA 

Lundbeckfonden Emerge

Nyheder

Dermtreat Announces First Patient Dosed in Phase 2b Clinical Trial of Rivelin Clobetasol for Oral Lichen Planus
28. juli 2018
Dermtreat sikrer GMP-produktion
4. september 2017
Lundbeckfonden investerer i CRISPR-teknologi til redigering af bakteriers gener
25. august 2017